trending Market Intelligence /marketintelligence/en/news-insights/trending/semc3ew18bgg_0nagw6vdq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Seattle Genetics stops clinical trials after patient deaths

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Seattle Genetics stops clinical trials after patient deaths

The U.S. FDA imposed a clinical hold on several Seattle Genetics Inc. trials evaluating the SGN-CD33A treatment for acute myeloid leukemia, a type of blood and bone marrow cancer.

The halt was initiated to assess the potential risk of hepatotoxicity, or chemical-driven liver damage, in patients who were treated with the drug and received stem cell transplants either prior to or after treatment.

Six patients were identified with hepatotoxicity, including several cases of veno-occlusive disease, with four fatal events, the company said.

As a result, two phase 1 trials have been placed on partial clinical hold while another phase 1/2 trial has been placed on full clinical hold.

Seattle Genetics is working with the regulator to determine a link between hepatotoxicity and the treatment to identify measures for patient safety.

Seattle Genetics' phase 3 trial of the drug in patients with acute myeloid leukemia and phase 1/2 trial in patients with myelodysplastic syndrome, another bone marrow disorder, are continuing.

New trials will not be initiated until the holds are lifted.